We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

170 hedge funds and large institutions have $398M invested in Allogene Therapeutics in 2023 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 22

10% more funds holding

Funds holding: 154 → 170 (+16)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less capital invested

Capital invested by funds: $413M → $398M (-$15.5M)

4% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 52

4.09% less ownership

Funds ownership: 77.73% → 73.64% (-4.1%)

79% less call options, than puts

Call options by funds: $96K | Put options by funds: $451K

Holders
170
Holders Change
+16
Holders Change %
+10.39%
% of All Funds
2.48%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
39
Increased
50
Reduced
52
Closed
22
Calls
$96K
Puts
$451K
Net Calls
-$355K
Net Calls Change
-$81K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$5.54M
2
Goldman Sachs
Goldman Sachs
New York
+$5.47M
3
Millennium Management
Millennium Management
New York
+$5.09M
4
BlackRock
BlackRock
New York
+$3.14M
5
Two Sigma Investments
Two Sigma Investments
New York
+$2.88M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$16.4M
2
EC
EcoR1 Capital
California
-$14.2M
3
WP
Woodline Partners
California
-$7.76M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$4.42M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
Qube Research & Technologies (QRT)
26
Qube Research & Technologies (QRT)
United Kingdom
$1.88M +$1.66M +585,706 New
Cerity Partners
27
Cerity Partners
New York
$1.66M +$1.47M +517,581 New
ECM
28
ExodusPoint Capital Management
New York
$1.49M +$1M +352,837 +321%
Renaissance Technologies
29
Renaissance Technologies
New York
$1.47M +$1.21M +428,366 +1,415%
PCIG
30
Partners Capital Investment Group
Massachusetts
$1.46M – – –
CBA
31
Coastal Bridge Advisors
Connecticut
$1.31M – – –
AAA
32
Affinity Asset Advisors
New York
$1.28M +$1.13M +400,000 New
ZIM
33
Zacks Investment Management
Illinois
$1.26M +$1.11M +392,443 New
Prudential Financial
34
Prudential Financial
New Jersey
$1.22M +$1.07M +378,840 New
N
35
Nuveen
North Carolina
$1.15M -$7.5K -2,643 -0.7%
Jane Street
36
Jane Street
New York
$1.15M +$937K +330,276 +1,239%
Bank of America
37
Bank of America
North Carolina
$1.06M -$1.43M -505,579 -60%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.04M +$37.3K +13,167 +4%
Norges Bank
39
Norges Bank
Norway
$869K -$1.08M -379,302 -58%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$800K -$219K -77,055 -24%
TD Asset Management
41
TD Asset Management
Ontario, Canada
$763K – – –
HF
42
HRT Financial
New York
$755K +$667K +235,333 New
Mitsubishi UFJ Asset Management
43
Mitsubishi UFJ Asset Management
Japan
$736K +$105K +37,131 +20%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$735K -$1.92M -675,395 -75%
SCM
45
Superstring Capital Management
New York
$713K +$630K +222,112 New
Swiss National Bank
46
Swiss National Bank
Switzerland
$690K +$63.5K +22,400 +12%
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$659K +$3.88K +1,369 +0.7%
Mirae Asset Global Investments
48
Mirae Asset Global Investments
South Korea
$627K -$661K -233,013 -54%
Ameriprise
49
Ameriprise
Minnesota
$611K +$158K +55,704 +41%
Barclays
50
Barclays
United Kingdom
$594K -$1.71M -601,886 -76%
1
2
3 4 5

ALLO Hedge Fund Activity: Q4 2023 in Review

170 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2023, worth a combined $398M — down 3.8% from $413M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new ALLO positions and 22 closed out — a net gain of 17 holders — while 50 added to existing stakes and 52 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $5.54M. The largest seller was State Street, cutting an estimated $16.4M.

  • 170 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2023, up from 154 in Q3 2023.
  • Funds reported $398M of Allogene Therapeutics stock for Q4 2023, down 3.8% quarter-over-quarter.
  • 39 funds opened new Allogene Therapeutics positions in Q4 2023 and 22 closed out, a net change of +17 holders.
  • The largest Allogene Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $5.54M added.
  • The largest Allogene Therapeutics seller in Q4 2023 was State Street, an estimated $16.4M sold.

Based on aggregated 13F filings for Q4 2023.